2017
Apr 13, 2017View PDF
Our clinical research and development center was established and commenced operation in Shanghai
We and Celgene established cooperation to develop and commercialize ATG-008 (onatasertib) in the APAC region
Our Group completed the Series A financing with an aggregate amount of approximately US$21 million
